Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

The immune system prevents recurrence of transplanted but not autochthonous antigenic tumors after oncogene inactivation therapy

[thumbnail of Accepted manuscript (final draft)]
Preview
PDF (Accepted manuscript (final draft)) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
20MB

Item Type:Article
Title:The immune system prevents recurrence of transplanted but not autochthonous antigenic tumors after oncogene inactivation therapy
Creators Name:Anders, K., Kershaw, O., Larue, L., Gruber, A.D. and Blankenstein, T.
Abstract:Targeted oncogene inactivation by small molecule inhibitors can be very effective but tumor recurrence is a frequent problem in the clinic. Therapy by inactivation of the cancer-driving oncogene in transplanted tumors was shown to be augmented in the presence of T cells. However, these experiments did not take into account the long-term, usually tolerogenic, interaction of de novo malignancies with the immune system. Here, we employed mice, in which SV40 large T (Tag) and firefly luciferase (Luc) as fusion protein (TagLuc) could be regulated with the Tet-on system and upon activation resulted in tumors after a long latency. TagLuc inactivation induced profound tumor regression, demonstrating sustained oncogene addiction. While tumor relapse after TagLuc inactivation was prevented in immunocompetent mice bearing transplanted tumors, autochthonous tumors relapsed or recurred after therapy discontinuation indicating that the immune system that coevolved with the malignancy over an extended period of time lost the potency to mount an efficient anti-tumor immune response. By contrast, adoptively transferred CD8(+) T cells targeting the cancer-driving oncogene eradicated recurrent autochthonous tumors, highlighting a suitable therapy option in a clinically relevant model.
Keywords:Small Moleculare Inhibitor, Oncogene Addiction, Immunogenic Cell Death, Autochthonous Tumor, Adoptive T Cell Therapy, Animals, Mice
Source:International Journal of Cancer
ISSN:0020-7136
Publisher:Wiley
Volume:141
Number:12
Page Range:2551-2561
Date:15 December 2017
Additional Information:Copyright © 2017 UICC [Union for International Cancer Control]
Official Publication:https://doi.org/10.1002/ijc.31009
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library